MapLight Q2 FY26 net loss widens to $60.19 million; R&D expenses rise to $53.44 million

• MapLight Therapeutics posted a Q2 net loss of $60.19 million, widening from $29.85 million a year earlier.
• R&D expenses climbed to $53.44 million from $26.85 million, driven by higher clinical trial and employee costs, including stock-based compensation.
• G&A costs rose to $10.11 million from $3.82 million on higher employee expenses, including stock-based compensation, and higher professional fees.
• Cash, cash equivalents and investments totaled $351.3 million at June 30; a $150 million private placement is expected to extend runway through 2028.
• Phase 2 ZEPHYR met its primary endpoint for ML-007C-MA in schizophrenia; Phase 3 ZEPHYR-2 topline results are expected in 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maplight Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608131605PRIMZONEFULLFEED9809758) on August 13, 2026, and is solely responsible for the information contained therein.